LEO CAPOBIANCO: Open Payments
NPI 1063483097 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,419 in 119 payments from 36 companies in 2025. Trend: 2023 $3,400 · 2024 $2,694 · 2025 $4,419
Food & beverage: $4,419
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 15 | $713 |
| ABBVIE INC. | 7 | $394 |
| Dexcom, Inc. | 9 | $378 |
| Abbott Laboratories | 5 | $357 |
| Lilly USA, LLC | 8 | $325 |
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $315 |
| Novo Nordisk Inc | 8 | $247 |
| Amgen Inc. | 6 | $217 |
| Edwards Lifesciences Corporation | 2 | $203 |
| ViiV Healthcare Company | 3 | $166 |
Products named: FREESTYLE LIBRE 3, Kerendia, Dexcom G6 Transmitter, BREZTRI, FARXIGA, AIRSUPRA, QULIPTA, SAPIEN 3 Ultra RESILIA.
Industry payments across NV — which companies pay providers there.
